When the body fights infection or injury, C-reactive protein rises, and laboratories have long used that signal to track inflammation. Today the C-reactive protein testing market is growing steadily as healthcare systems face more chronic disease and look for fast, affordable markers. Polaris Market Research puts the market at USD 2.9 billion in 2024 and USD 3.16 billion in 2025, with a forecast of USD 6.7 billion by 2034 at a CAGR of 8.80%.

How the Market Is Structured

The market is segmented by assay type, detection range, disease area, end use and region. Assay types include immunoturbidimetric assays, ELISA and chemiluminescence immunoassays, with immunoturbidimetric methods holding the largest share in 2024. Detection ranges cover high-sensitivity, conventional and cCRP formats. Disease areas include cardiovascular disease, cancer, rheumatoid arthritis, inflammatory bowel disease, endometriosis and lupus, while buyers range from hospitals, clinics and laboratories to assisted living facilities and home care settings.

What Is Driving Growth

Cardiovascular disease is the biggest driver. Elevated CRP is linked with inflammation in the heart and blood vessels, so testing is used to help gauge risk alongside factors such as blood pressure, cholesterol and diabetes. Aging populations are another force, since older adults face greater risk of chronic inflammatory conditions. Rising healthcare investment and the use of CRP in assessing infection severity, a role that became more visible during the COVID-19 pandemic, add further momentum.

Government interest also helps. Public initiatives that promote point-of-care screening and newer testing techniques aim to make cardiovascular diagnosis and monitoring more accessible and convenient. Polaris notes that the United States recorded more than 356,000 out-of-hospital cardiac arrests in 2019, a reminder of why risk markers draw so much attention.

Industry Trends

Sensitivity and Speed

High-sensitivity formats are expected to expand fastest, supported by point-of-care devices and research into nano-bio hybrid biosensors for rapid, accurate measurement. Abbott’s Afinion CRP and Aidian’s QuikRead go CRP are examples of compact systems built for quick results.

Digital Tools

Artificial intelligence is starting to shape the field by automating interpretation, reducing manual errors and linking CRP values with patient histories. HORIBA’s September 2025 partnership with GeodAIsics on early sepsis detection shows how CRP-enabled analyzers may feed such tools.

Consolidation

Quest Diagnostics completed the acquisition of select clinical testing assets from Spectra Laboratories in August 2025, reflecting continued activity among large laboratory networks.

Research and Innovation

Academic work is feeding the product pipeline. A 2021 study from Babeș-Bolyai University in Romania reviewed assays based on plasmonic nanoparticles for detecting CRP, along with newer point-of-care formats for rapid testing. Researchers in India have applied a latex-enhanced immunoturbidimetric assay for highly sensitive, wide-range detection in human serum, and a Korean study has outlined electrical and electrochemical biosensors built from nanomaterial hybrids. Together these projects point toward smaller, faster and more precise testing tools.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/c-reactive-protein-testing-market 

The Role of Artificial Intelligence

Polaris lists several ways AI could change CRP workflows. It can sharpen analysis by automating interpretation, detect inflammation-linked patterns in large datasets, support clinical decisions by cross-referencing CRP values with patient history, and make laboratories more efficient and less costly. These gains may matter most in high-volume laboratories, where small improvements in turnaround time add up.

Regions, Barriers and Competition

North America leads because of its high cardiovascular burden and advanced facilities, while Asia Pacific is expected to be the fastest-growing region, with hospital adoption rising alongside the prevalence of malaria and cardiovascular disease. High costs and uneven reimbursement hold back adoption, and the marker’s limited specificity means results need careful clinical interpretation. Competition is intense and shaped by innovation, collaboration and research. Notable companies include:

• Abbott
• Aidian
• Abaxis, Inc.
• BODITECH MED, INC.
• HORIBA, Ltd.
• Ortho Clinical Diagnostics
• Randox Laboratories Ltd.
• Roche Ltd.
• Thermo Fisher Scientific
• Quest Diagnostics

Conclusion

Demand for C-reactive protein testing rests on solid ground: more chronic disease, older populations and a clear need for quick inflammation markers. The next phase will reward companies that improve sensitivity, shorten turnaround times and help laboratories automate. Cost and reimbursement challenges remain, but the long-term direction points toward wider and faster testing.

More Trending Latest Reports By Polaris Market Research:

Waterproofing Membranes Market Trends

Wallpaper Market Size

Yacht Market Share

Sourdough Market Growth

Dropshipping Market Forecast

Ai In Infrastructure Market Analysis

Cryptocurrency Market Opportunities

Jewelry Market Trends

Food Inclusions Market Size